21st Austria weekly - Valneva; UBM (03/12/2024)

Valneva: Valneva SE, a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ^®. The results are in line with Valneva’s expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated. Among the 278 healthy adults still enrolled in the trial, 96% maintained neutralizing antibody titers well above the seroresponse threshold three years after the single-dose vaccination. Persistence of antibodies in older adults (age 65+) in terms of geometric mean titers (GMTs) and seroresponse rates (SRRs) was comparable to younger adults (18-64 years of age). Hence, the primary endpoint was met.
Valneva: weekly performance: 4.61%

UBM: UBM Development is selling a non-core asset in Poland for €17.85m to a polish entity – Rewa prosta spółka akcyjna (simple joint stock company) with its registered office in Cracow. The project Galeria Szperk is a shopping center with 57 well-known chains, national and local brands, including attractive retail and service outlets in Kosakowo (Gdynia), Poland. Thomas G. Winkler, CEO of UBM Development AG, explains: “Liquidity over profitability is UBM’s mantra in 2024 and our transaction in Gdynia lives up to this approach.”
UBM: weekly performance: -6.47%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (03/12/2024)

Christian Drastil: Wiener Börse Plausch

kapitalmarkt-stimme.at daily voice 19/365: Zahlen/Fakten nach Woche 3, damit man bzgl. Wiener Börse mitreden und sie einreihen kann

Bildnachweis

1. 21st Austria Weekly

Aktien auf dem Radar:Lenzing, Amag, Warimpex, Pierer Mobility, AT&S, Immofinanz, ATX Prime, voestalpine, Andritz, EVN, Semperit, VIG, Rosgix, Verbund, Wienerberger, EuroTeleSites AG, CA Immo, Agrana, Palfinger, Wolford, SBO, Kapsch TrafficCom, Strabag, Frequentis, Zumtobel, RHI Magnesita, Heid AG, Oberbank AG Stamm, FACC, Flughafen Wien, OMV.

Random Partner

---

Valneva
Valneva ist ein Impfstoffunternehmen, das sich auf die Entwicklung und Vermarktung von prophylaktischen Impfstoffen gegen Infektionskrankheiten mit hohem ungedeckten medizinischen Bedarf spezialisiert hat.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner